RCE recce pharmaceuticals ltd

Ann: Positive Safety Data from Phase 1 Clinical Trial, page-3

  1. 3,372 Posts.
    lightbulb Created with Sketch. 1898
    Positive Safety Data from First Cohort of Phase I
    Clinical Trial Evaluating Healthy Subjects
    Intravenously Dosed with RECCE®327
    Highlights:
    9 subjects in cohort one intravenously dosed with RECCE®327 at 50mg meet sall
    end-points, indicating to be safe and well tolerated
    Independent Safety Committee clears second study cohort to be dosed at 150mg
    -a three fold increase in dose per approved protocol
    Second cohort recruited; healthy subjects to be dosed 7January 2022

 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
29.0¢
Change
0.000(0.00%)
Mkt cap ! $83.62M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
1 20000 29.0¢
 

Sellers (Offers)

Price($) Vol. No.
30.5¢ 915 1
View Market Depth
Last trade - 10.00am 25/06/2025 (20 minute delay) ?
RCE (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.